Search research articles
Contact Us
Filters
Showing results (131-140 of 418) with videos related to
Page
of 42
Sort By:
JAMA Oncology
|
August 4, 2018
Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600-Mutated Metastatic Melanoma: Pooled Analysis of 4 Randomized Clinical Trials
Axel Hauschild, James Larkin, Antoni Ribas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 9, 2021
Plasma KIM-1 Is Associated with Recurrence Risk after Nephrectomy for Localized Renal Cell Carcinoma: A Trial of the ECOG-ACRIN Research Group (E2805)
Wenxin Xu, Mäneka Puligandla, Brian Halbert, et al.
Journal of Translational Medicine
|
August 5, 2020
Impact of initial treatment and prognostic factors on postprogression survival in BRAF-mutated metastatic melanoma treated with dacarbazine or vemurafenib ± cobimetinib: a pooled analysis of four clinical trials
Paolo A Ascierto, Antoni Ribas, James Larkin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 17, 2015
BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma--A Trial of the ECOG-ACRIN Cancer Research Group (E2804)
Keith T Flaherty, Judith B Manola, Michael Pins, et al.
Molecular Cancer Therapeutics
|
April 26, 2013
CRM1 and BRAF inhibition synergize and induce tumor regression in BRAF-mutant melanoma
Roberto A Salas Fragomeni, Hye Won Chung, Yosef Landesman, et al.
The Lancet. Oncology
|
November 20, 2016
Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials
Georgina V Long, Jean-Jacques Grob, Paul Nathan, et al.
Nature Reviews. Drug Discovery
|
September 7, 2013
Considerations for the successful co-development of targeted cancer therapies and companion diagnostics
Jane Fridlyand, Richard M Simon, Jessica C Walrath, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 23, 2025
Facts and Hopes: Toward the Next Quantum Leap in Melanoma
Keith T Flaherty, Andrew E Aplin, Michael A Davies, et al.
Journal of the American Academy of Dermatology
|
August 21, 2016
Ki-67, p53, and p16 expression, and G691S RET polymorphism in desmoplastic melanoma (DM): A clinicopathologic analysis of predictors of outcome
Nicholas F Lawrence, Marc R Hammond, Dennie T Frederick, et al.
Cancer Chemotherapy and Pharmacology
|
January 15, 2004
Phase I trial of the antifolate ZD9331 in combination with cisplatin in patients with refractory solid malignancies
Joshua H Bilenker, James P Stevenson, Keith T Flaherty, et al.
Page
of 42
Search research articles
Search
Showing results (131-140 of 418) with videos related to
Sort By:
Page
of 42
JAMA Oncology
|
August 4, 2018
Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600-Mutated Metastatic Melanoma: Pooled Analysis of 4 Randomized Clinical Trials
Axel Hauschild, James Larkin, Antoni Ribas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 9, 2021
Plasma KIM-1 Is Associated with Recurrence Risk after Nephrectomy for Localized Renal Cell Carcinoma: A Trial of the ECOG-ACRIN Research Group (E2805)
Wenxin Xu, Mäneka Puligandla, Brian Halbert, et al.
Journal of Translational Medicine
|
August 5, 2020
Impact of initial treatment and prognostic factors on postprogression survival in BRAF-mutated metastatic melanoma treated with dacarbazine or vemurafenib ± cobimetinib: a pooled analysis of four clinical trials
Paolo A Ascierto, Antoni Ribas, James Larkin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 17, 2015
BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma--A Trial of the ECOG-ACRIN Cancer Research Group (E2804)
Keith T Flaherty, Judith B Manola, Michael Pins, et al.
Molecular Cancer Therapeutics
|
April 26, 2013
CRM1 and BRAF inhibition synergize and induce tumor regression in BRAF-mutant melanoma
Roberto A Salas Fragomeni, Hye Won Chung, Yosef Landesman, et al.
The Lancet. Oncology
|
November 20, 2016
Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials
Georgina V Long, Jean-Jacques Grob, Paul Nathan, et al.
Nature Reviews. Drug Discovery
|
September 7, 2013
Considerations for the successful co-development of targeted cancer therapies and companion diagnostics
Jane Fridlyand, Richard M Simon, Jessica C Walrath, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 23, 2025
Facts and Hopes: Toward the Next Quantum Leap in Melanoma
Keith T Flaherty, Andrew E Aplin, Michael A Davies, et al.
Journal of the American Academy of Dermatology
|
August 21, 2016
Ki-67, p53, and p16 expression, and G691S RET polymorphism in desmoplastic melanoma (DM): A clinicopathologic analysis of predictors of outcome
Nicholas F Lawrence, Marc R Hammond, Dennie T Frederick, et al.
Cancer Chemotherapy and Pharmacology
|
January 15, 2004
Phase I trial of the antifolate ZD9331 in combination with cisplatin in patients with refractory solid malignancies
Joshua H Bilenker, James P Stevenson, Keith T Flaherty, et al.
Page
of 42